CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry #VisualAbstract: Cagrilintide Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes 2 Minute Medicine